Pregabalin and duloxetine for the treatment of neuropathic pain disorders.
Clinical studies investigating the use of pregabalin and duloxetine for the management of diabetic peripheral neuropathy and post-herpetic neuralgia are reviewed. The benefits and potential drawbacks associated with these agents are discussed.
Terneus
William
W
Interdisciplinary Pain and Palliative Care and Integrative Medicine Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA. william.terneus@irmh.org
D000588:Amines / Q000627:therapeutic use*; D000700:Analgesics / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D000068736:Duloxetine Hydrochloride; D000077206:Gabapentin; D006801:Humans; D009437:Neuralgia / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D000069583:Pregabalin; D016032:Randomized Controlled Trials as Topic; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
D000588:Amines; D000700:Analgesics; D003509:Cyclohexanecarboxylic Acids; D013876:Thiophenes; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D000068736:Duloxetine Hydrochloride